AzTrials
AzTrials

Pancreas CancerDALCUTNCT04380506

Validations of New cut-of for the Stratification of Postoperative Complications,Drains Management

A study testing Surgical Drains Management in people with Pancreas Cancer and Pancreatic Fistula, run by Campus Bio-Medico University at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Pancreatic fistula (PF) represents the Achille's heel of pancreatic surgery and is the main cause of postoperative morbidity since it can determine the onset of others complications such as abdominal abscesses, surgical wound infections, sepsis and bleeding, that can sometimes be fatal. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Pancreas Cancer, Pancreatic Fistula
What is being tested?
Surgical Drains Management
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
165 participants
Where
1 siteItaly
Study dates
15 Mar 2020to 1 Sep 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • age > 18 years old
  • acquisition of informed consent for surgery and for inclusion in the study;
  • elective open or laparoscopic PD

Who cannot join

  • age <to 18 years;
  • absence of informed consent for inclusion in the study;
  • Emergency surgery;
  • other pancreatic resections (not PD).

Trial locations and contacts

1 site in 1 country.

Italy1 site, 1 recruiting
  • University Hospital Campus Bio-Medico of Rome

    Roma, 00128

    Damiano Caputo, MD, d.caputo@unicampus.it

    Vincenzo La Vaccara, MD, PhD

    Recruiting

Other trials in Italy

About this study

Official title: Drain Amylase Levels After Pancreatoduodenectomy. Validations of New cut-of for the Stratification of Postoperative Complications, Surgical Drains Management and Use of Postoperative Abdominal CT: (The DALCUT) Trial

Pancreatic fistula (PF) represents the Achille's heel of pancreatic surgery and is the main cause of postoperative morbidity since it can determine the onset of others complications such as abdominal abscesses, surgical wound infections, sepsis and bleeding, that can sometimes be fatal.

During a previous study conducted at the University Campus Bio-Medico of Rome, Department of General Surgery there were identified cut-offs of amylase levels on the abdominal drainage fluid dosed in I postoperative day (POD1) and III postoperative day (POD3) which can significantly predict PF and in particular clinically relevant fistulas as well as abdominal collections and biliary fistulas, if related to some specific findings of the abdominal CT routine performed in POD3.

The aim of this research project is to validate the cut-offs of the amylase levels on drainage fluid identified during the previous research in order to identify patients at risk of clinically relevant PF and to validate the use of abdomen CT without contrast in POD3 in patients with increased risk of biliary fistula.

Read the detailed description

Pancreatic Fistula (PF) remains the main complication following pancreatic surgery with an incidence described in up to 45% of cases, even in high volume centers. It can determine the onset of other complications such as abdominal abscesses, surgical wound infections, sepsis and bleeding, sometimes fatal. In addition, the economic impact due to the extension of hospital stay and the management costs of the PF are not of secondary importance.

The International Study Group on Pancreatic Fistula (ISGFP) has standardized the definition of PF identifying it as "the leak from a surgical or percutaneous drainage of any measurable quantity of fluid, starting from the third postoperative day (POD3), with an amylase content three times higher than the upper normal limit of serum amylases. " However, according to this definition, all patients who satisfy this condition, even in the absence of any clinical signs or symptoms, are defined as suffering from pancreatic fistula.

To overcome this, a three grades classification system of PF was introduced, based on the clinical impact:

  • Grade A: It is biochemical fistula; No intervention needed, not significant change of the post-operative hospital stay.
  • Grade B: it requires an extension of the post-operative hospital stay, the permanence of surgical drains, the possible positioning of further drainages under radiological guide, antibiotic therapy and the use of artificial, enteral or parenteral nutrition;
  • grade C: re-surgery is needed. Grade B and C represent clinically relevant fistulas. It is therefore evident that a correct definition of PF and its grade (A, B, C) can only be formulated "a posteriori".

However, considering the high prognostic impact of PF, it is needful to identify risk factors and diagnostic tools capable of stratifying patients at risk of pancreatic fistula and reach an early diagnosis in order to plan better plan both the treatment of it and the complications that may arise.

Many authors assume that the main predictive factor of PF is represented by the level of amylases in the abdominal drainage fluid, at different cut-offs and on different postoperative days. Others assume that abdominal drainage itself determines the development of PF and other complications.

Molinari has shown that a level of amylase in the abdominal drainage fluid <5000 IU / L in POD1 identifies a subgroup of patients at low risk of PF in which abdominal drainage is unfavorable to maintain. In Molinari's work, however, patients with PF grade A were also considered.

In his experience, Fong has identified a high-risk of PF subgroup in patients underwent DCP with an amylase level in abdominal drainage fluid > 600 IU / L in POD1. The author therefore proposed the immediate removal of abdominal drainage in patients considered low risk.

One of the most consistent bias of the Fong study is that in some patients there was an intrapancreatic drainage connected to the outside. Recently, Seykora has shown how in patients underwent DCP it is possible to use different amylase level cutoffs on drainage fluid in POD1, POD3 and POD5 in order to predict the clinically relevant PF risk and modulate the management of surgical drainages.

One of the limitations of the cut-offs identified by Seykora is represented by the fact that they have been identified considering their negative predictive value rather than their positive predictive value.

In a study recently conducted at Campus Bio-Medico University of Rome, Caputo confirmed that the dosage of amylase on the abdominal drainage fluid represents the most important clinically relevant predictor of PF and has confirmed, as underlined by Seykora, that the management of abdominal drainage is necessarily a dynamic process conditioned mainly by the serial dosage of amylases on drainage liquid (POD1-3).

Furthermore, in the Caputo's work, cut-offs of amylases on the abdominal drainage liquid (> 666 IU / L in POD1 and> 252 IU / L in POD3) have been identified as able to predict more than 80% of the clinically relevant PF. It has also been shown that the value of the amylases on the abdominal drainage fluid in POD3> 207 IU / L and the presence of an abdominal collection of dimensions equal to or greater than 5 cm in the abdomen CT without contrast performed on the same day significantly correlates with the risk of developing a biliary fistula.

If confirmed by this study, the practice of maintaining drainage in place up to POD3 could be validated. Drainages could be removed in POD3 in case of amylase levels in POD1 <666 U / L and amylase levels in POD3 <252 U / L except in cases where the amylase levels in POD3 are ≥ 207 and for which the routine use of abdominal CT on the same day seems to be justified in order to detect abdominal collections ≥ 5 cm which confirm the risk of this complication. In this latter category of patients, considering the risk of biliary fistula, drainages could be maintained beyond POD3.

Being tested
Surgical Drains Management
Keywords
Surgical Drain Managment, Pancreatic Fistula, Postoperative Complication, Amylase Drain level
Medical subject headings
Pancreatic Neoplasms, Pancreatic Fistula, Postoperative Complications

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Surgical Drains ManagementProcedure or surgery

    The Role of Amylase Drain Level in the Management of Surgical Drains after Pancreratoduodenectomy

Study groups in NCT04380506
Study groupRoleWhat they receive
Drain removalExperimentalPatients that fulfill criteria for surgical drains removal
Receives: Procedure: Surgical Drains Management

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Validate the cut-offs of the amylase levels on drainage fluid identified during the previous research in order to identify patients at risk of clinically relevant FP

    The management of drainages and the execution of the abdomen CT scan in Postoperative day 3 will be managed on the basis of the outcome of the assay of amylase levels performed on fluid collected by surgical drains. This evaluation will be performed each day in the first three postoperative days or until drains removal.

    Measured: From postoperative day 1 to postoperative day 90

  2. Validate the ability of the diameter (in cm) of abdominal collection detected during the contrast-free abdomen CT in POD3 to predict risk of biliary fistula

    The relation between abdominal collections (measured in centimeters) detected with abdomen CT scan and the risk of develop a biliary fistula.

    Measured: From postoperative day 1 to postoperative day 90

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 May 2020
  2. Study start15 Mar 2020
  3. Primary completion1 Jun 2021 (estimated)
  4. Study completion1 Sep 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
165 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04380506
Sponsor's protocol ID
24/20 PAR ComEt CBM
Acronym
DALCUT
Status last verified
May 2020
First submitted
21 Apr 2020
Last updated
8 May 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Surgical Drains Management in people with Pancreas Cancer and Pancreatic Fistula, run by Campus Bio-Medico University at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 8 May 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Andrea Rossi (0039225411257, a.rossi@unicampus.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Validate the cut-offs of the amylase levels on drainage fluid identified during the previous research in order to identify patients at risk of clinically relevant FP (time frame: From postoperative day 1 to postoperative day 90). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in